Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, January 9, 2026

Neuromarkers of Adaptive Neuroplasticity and Cognitive Resilience Across Aging: A Multimodal Integrative Review

 Have your competent? doctor write this up into COMPREHENSIVE, UNDERSTANDABLE EXACT PROTOCOLS!

Failure to do so is fireable along with removing the board of directors for hiring standards so bad this person was hired!

Neuromarkers of Adaptive Neuroplasticity and Cognitive Resilience Across Aging: A Multimodal Integrative Review


,
,
,
,
,
and
1
Facultad de Medicina, Universidad Autónoma de Guadalajara, Guadalajara 45129, Mexico
2
Facultad de Medicina, Universidad Autónoma del Estado de México, Toluca 50180, Mexico
3
Facultad de Medicina, Universidad Lamar, Guadalajara 44110, Mexico
4
Facultad de Medicina, Universidad Autónoma de Tamaulipas, Victoria 87149, Mexico
This article belongs to the Section Aging Neuroscience

Abstract

Background: Aging is traditionally characterized by progressive structural and cognitive decline; however, increasing evidence shows that the aging brain retains a remarkable capacity for reorganization. This adaptive neuroplasticity supports cognitive resilience—defined as the ability to maintain efficient cognitive performance despite age-related neural vulnerability. Objective: To synthesize current molecular, cellular, neuroimaging, and electrophysiological neuromarkers that characterize adaptive neuroplasticity and to examine how these mechanisms contribute to cognitive resilience across aging. Methods: This narrative review integrates findings from molecular neuroscience, multimodal neuroimaging (fMRI, DTI, PET), electrophysiology (EEG, MEG, TMS), and behavioral research to outline multiscale biomarkers associated with compensatory and efficient neural reorganization in older adults. Results: Adaptive neuroplasticity emerges from the coordinated interaction of neurotrophic signaling (BDNF, CREB, IGF-1), glial modulation (astrocytic lactate metabolism, regulated microglial activity), synaptic remodeling, and neurovascular support (VEGF, nitric oxide). Multimodal neuromarkers—including preserved frontoparietal connectivity, DMN–FPCN coupling, synaptic density (SV2A-PET), theta–gamma coherence, and LTP-like excitability—consistently correlate with resilience in executive functions, memory, and processing speed. Behavioral enrichment, physical activity, and cognitive training further enhance these biomarkers, creating a bidirectional loop between experience and neural adaptability. Conclusions: Adaptive neuroplasticity represents a fundamental mechanism through which older adults maintain cognitive function despite biological aging. Integrating molecular, imaging, electrophysiological, and behavioral neuromarkers provides a comprehensive framework to identify resilience trajectories and to guide personalized interventions aimed at preserving cognition. Understanding these multilevel adaptive mechanisms reframes aging not as passive decline but as a dynamic continuum of biological compensation and cognitive preservation.

1. Introduction

Aging is accompanied by complex neurobiological changes that modify the structure and function of the brain. For decades, this process was primarily described in terms of decline—characterized by synaptic loss, reduced neurogenesis, and progressive cognitive impairment [1,2,3,4]. However, recent evidence challenges this unidirectional view by showing that the aging brain retains a remarkable capacity for adaptation and reorganization, a phenomenon known as adaptive neuroplasticity [1,4,5,6,7].
Neuroplasticity encompasses the brain’s ability to modify neural circuits in response to internal or external stimuli, maintaining homeostasis and optimizing cognitive performance [1,4,8,9,10,11,12]. In older adults, adaptive plasticity can manifest as compensatory recruitment of alternative neural pathways, strengthening of residual synapses, or increased functional connectivity within critical cognitive networks [2,5,6,7,10,13]. These compensatory mechanisms are thought to underlie cognitive resilience, defined as the ability to maintain functional cognition despite age-related structural or molecular changes [13,14,15,16,17,18,19].
Understanding the biological basis of this adaptive capacity has led to increasing interest in neuromarkers—objective indicators of neural processes that reflect the state or efficiency of neuroplastic mechanisms. Neuromarkers can be derived from multiple levels of analysis, including molecular signatures such as BDNF, CREB, and synapsin [20,21,22,23,24,25,26,27,28], neuroimaging correlates linked to network reorganization or connectivity [2,29,30,31,32,33,34,35,36,37,38,39], and electrophysiological measures of cortical excitability and oscillatory dynamics [40,41,42,43,44,45]. Integrating these multimodal biomarkers provides a framework for identifying how some individuals sustain high cognitive performance despite structural brain aging [17,18,19,46,47,48].
This review aims to synthesize current evidence linking neuromarkers of adaptive neuroplasticity to cognitive resilience across aging. By bridging molecular, imaging, and behavioral domains, it seeks to clarify how plasticity-related processes contribute to the preservation of cognition and to highlight emerging biomarkers that may guide early detection and preventive interventions against cognitive decline [18,19,49,50].

8. Discussion

The growing evidence summarized in this review supports a paradigm shift in the understanding of brain aging—from a model of progressive decline to one of dynamic adaptation [2,3,4,5,6,7,8,11,12,13,51,52]. Rather than a passive loss of neural resources, the aging brain displays a remarkable ability to reorganize its structure and function to preserve cognition [15,16,20,45,46,47,48,53,70,71,72,85]. This adaptive neuroplasticity, underpinned by molecular, glial, and vascular mechanisms, constitutes the biological substrate of cognitive resilience [21,22,23,24,25,26,27,28,31,55,56,57,58,59,60,61,62,63,64,65,69].
Importantly, neuromarker interpretation in aging should not rely on a simplified linear framework in which higher values are automatically equated with adaptive neuroplasticity or preserved neural health [25,26,56,57]. In older adults, increases in neuromarkers such as BDNF expression, functional connectivity strength, or regional metabolic activity may reflect compensatory responses to declining efficiency in downstream signaling pathways rather than enhanced function per se [27,28,58,59]. Evidence from neuroimaging and molecular studies indicates that such compensatory upregulation may coexist with reduced network efficiency, altered excitation–inhibition balance, or increased energetic cost during cognitive performance [60,61,62,63].
In addition, aging-related neuromarkers should not be interpreted independently of age range, cognitive status, or measurement context. Neuroimaging and electrophysiological metrics obtained during resting-state conditions may index baseline network organization, whereas task-based measures more directly reflect compensatory recruitment or neural efficiency under cognitive demand [32,33,34,35,36]. Importantly, these patterns vary across the aging spectrum, with younger-old adults often exhibiting flexible compensatory engagement, while older-old individuals may show overactivation associated with reduced performance or increased neural cost [37,38,39,40,41].
Thus, the functional meaning of a given neuromarker is context-dependent and influenced by age range, cognitive status, task demands, and interactions with other biological signals, including inflammatory and vascular factors [64,65,66,69]. As a result, similar neuromarker profiles may carry fundamentally different implications in cognitively resilient older adults compared with individuals at risk for cognitive decline, underscoring the need for cautious and integrative interpretation when evaluating biomarkers of adaptive plasticity in aging populations [29,30,31,67].
However, the heterogeneity of findings across studies underscores that neuroplasticity is not uniformly beneficial. Some compensatory activations may reflect inefficiency rather than resilience, particularly when overactivation of frontal or parietal networks accompanies declining cognitive performance [17,45,46,47,48,72,85,101]. Disentangling adaptive from maladaptive reorganization therefore remains a major conceptual challenge. Future research should integrate longitudinal designs and mechanistic approaches to distinguish compensatory recruitment that sustains function from neural responses that precede cognitive exhaustion [17,18,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,54,66,67,70,71,72,74,75,82,99,100,101,102].
Another critical point concerns the bidirectional relationship between behavior and biology. Lifestyle factors—such as physical activity, intellectual engagement, and social interaction—can modulate neurotrophic signaling, network organization, and metabolic efficiency [21,22,23,24,49,50,55,88,89,90,91,92,93,94,95], thereby creating a feedback loop between experience and brain biology. Conversely, molecular deficits, including reduced BDNF availability or impaired neurovascular coupling, may constrain the effectiveness of behavioral interventions [21,22,23,24,25,26,27,28,55,56,57,60,61,62]. This interplay highlights the necessity of multilevel models that integrate molecular, network, and behavioral dimensions to fully capture the determinants of cognitive resilience [17,18,45,46,47,48,54,72,75,85,99,100,101,102].
Beyond biological factors, environmental and experiential determinants play a critical role in shaping adaptive neuroplasticity and cognitive resilience in aging. Educational attainment, occupational complexity, physical activity, and sustained cognitive engagement have been consistently associated with more efficient network organization, preserved functional connectivity, and modulation of neurotrophic signaling pathways in older adults [21,22,23,24,49,50,55,88,89,90,91,92,93,94,95]. These factors contribute to cognitive reserve, influencing how neural systems respond to age-related stressors and modifying the functional expression of neuromarkers observed in neuroimaging and molecular studies.
Consequently, similar neuromarker profiles may therefore reflect distinct underlying mechanisms depending on an individual’s environmental background and life-course exposures. For example, increased functional connectivity or metabolic activity may support resilience in individuals with higher cognitive reserve, while representing compensatory strain or inefficiency in less enriched contexts [17,18,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,54,66,67,72,74,75,82,99,100,101,102]. Integrating environmental determinants into neuromarker-based models is thus essential for accurate interpretation and for advancing precision approaches to cognitive aging.
Importantly, resilience should not be conflated with resistance to aging, but rather conceptualized as adaptive recalibration in response to age-related biological change [17,18,54,70,71,72,99,100,101,102]. The presence of preserved or reorganized neural networks does not imply the absence of pathology, but instead reflects the engagement of compensatory mechanisms that maintain functional homeostasis [17,45,46,47,48,72,85,101]. Integrating multimodal neuromarkers within this framework enables a more nuanced view of brain aging—one characterized not by inevitable loss, but by the dynamic balance between degeneration and adaptation. This perspective aligns with the emerging paradigm of precision cognitive aging, which emphasizes individualized trajectories shaped by biological, environmental, and experiential factors [19,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,54,66,67,74,75,82,83,84,85,86,102].

9. Conclusions

Adaptive neuroplasticity represents a central mechanism through which the aging brain preserves cognitive function and reorganizes itself in response to biological and environmental demands [5,6,7,11,12,13,17,18,51,52,54,70,71,72,99,100,101,102]. Rather than a passive trajectory of decline, aging reflects a continuous interplay between degeneration and compensation—an evolving equilibrium shaped by molecular, glial, vascular, and network-level processes [15,16,17,18,19,20,27,28,31,44,45,46,47,48,53,54,58,59,60,61,62,63,64,65,69,70,71,72,83,84,85,86,99,100,101,102].
Neuromarkers such as BDNF, CREB, IGF-1, VEGF, indices of synaptic integrity, functional connectivity, white-matter structure, and cortical excitability provide quantifiable windows into these adaptive mechanisms [19,21,22,23,24,25,26,27,28,37,38,39,40,41,55,56,57,58,59,60,61,62,83,84]. Importantly, physiological measures of plasticity obtained through non-invasive brain stimulation—including TMS, tDCS, paired associative stimulation, and theta-burst paradigms—offer robust biomarkers of cortical adaptability across the lifespan [77,78,79,80,81,96,97,98,103,104,108,109]. These neurophysiological signatures complement molecular and imaging-based neuromarkers, strengthening multimodal models of aging [78,79,96,97,98,103,104].
Integrating neuromarkers across biological scales—from cellular metabolism and neurotrophic signaling to network reorganization and behavioral performance—provides a unified framework to understand how cognitive resilience emerges from plasticity [17,18,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,45,46,47,48,54,66,67,70,71,72,74,75,82,85,99,100,101,102]. Evidence that cortical plasticity varies across individuals, influenced by genetic, lifestyle, and neurobiological factors, further reinforces the need for personalized models of aging [80,81,103,104].
The convergence of molecular neuroscience, multimodal imaging, electrophysiology, and cognitive science demonstrates that plasticity and vulnerability coexist across the lifespan [17,18,45,46,47,48,54,70,71,72,85,99,100,101,102]. The future of aging research will depend on the development of composite biomarker signatures, incorporation of TMS- and EEG-based plasticity metrics, and implementation of personalized interventions guided by individual plasticity fingerprints [19,44,45,46,47,48,49,50,54,74,75,78,79,80,81,82,83,84,85,86,88,89,90,91,92,93,94,95,96,97,98,102,103,104].
Recognizing neuroplasticity as a lifelong capacity reframes aging not as a trajectory of inevitable decline, but as a dynamic continuum of biological adaptability and cognitive resilience [17,18,19,44,45,46,47,48,54,68,70,71,72,73,76,80,81,83,84,85,86,87,99,100,101,102,103,104,105,106,107,110,111].
More at link above the discussion section.

Measuring arm function early after stroke: is the DASH good enough?

 

Are you THAT BLITHERINGLY STUPID that you think 'measurements' DO ONE GODDAMN THING TOWARDS RECOVERY?

I don't think there are two functioning neurons anywhere among stroke medical 'professionals'!

Measuring arm function early after stroke: is the DASH good enough?

 Karen Baker 1, 
Louise Barrett 2, 
E Diane Playford 1, 
Trefor Aspden 3,  
Afsane Riazi 3, 
Jeremy Hobart 2 
Correspondence to Professor Jeremy Hobart, Clinical Neurology Research Group, Plymouth University Peninsula Schools of Medicine and Dentistry, Room N13 ITTC Building, Plymouth Science Park, Derriford, Plymouth PL6 8BX, UK; jeremy.hobart@plymouth.ac.uk
 From: 
1 Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, London, UK;  
2 Department of Psychology, Royal Holloway University of London, Egham, Surrey, UK;  
3 Clinical Neurology Research Group, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth

Abstract

Objective Despite a growing call to use patient-reported outcomes in clinical research, few are available for measuring upper limb function post-stroke. We examined the Disabilities of the Arm, Shoulder and Hand (DASH) to evaluate its measurement performance in acute stroke. In doing so, we compared results from traditional and modern psychometric methods.

Methods 172 people with acute stroke completed the DASH. Those with upper limb impairments completed the DASH again at 6 weeks (n=99). Data (n=271) were analysed using two psychometric paradigms: traditional psychometric (Classical Test Theory, CTT) analyses examined data completeness, scaling assumptions, targeting, reliability and responsiveness; Rasch Measurement Theory (RMT) analyses examined scale-to-sample targeting, scale performance and person measurement.

Results CTT analyses implied the DASH was psychometrically robust in this sample. Data completeness was high, criteria for scaling assumptions were satisfied (item-total correlations 0.55–0.95), targeting was good, internal consistency reliability was high (Cronbach's α=0.99) and responsiveness was clinically moderate (effect size=0.51). However, RMT analyses identified important limitations: scale-to-sample targeting was suboptimal, 4 items had disordered response category thresholds, 16 items exhibited misfit, 3 pairs of items had high residual correlations (>0.60) and 84 person fit residuals exceeded the recommended range.

Conclusions RMT methods identified limitations missed by CTT and indicate areas for improvement of the DASH as an upper limb measure for acute stroke. Findings, similar to those identified in multiple sclerosis, highlight the need for scales to have strong conceptual underpinnings, with their development and modification guided by sophisticated psychometric methods.


Predicting activities of daily living at discharge in stroke patients using rehabilitation robot training-induced functional connectivity

I don't consider any prediction of recovery useful at all. You're supposed to deliver EXACT RECOVERY PROTOCOLS AS SURVIVORS NEED! This is fucking useless for survivors! You're fired!

'Assessments' don't get you recovered, only EXACT PROTOCOLS DO! SURVIVORS WANT RECOVERY! GET THERE!

I'd fire everyone involved with this crapola! You're 'assessing' based on the failure of the status quo! Change the status quo, you blithering idiots!

 Predicting activities of daily living at discharge in stroke patients using rehabilitation robot training-induced functional connectivity


ABSTRACT


Background
Predicting activities of daily living (ADL) in stroke patients optimizes discharge planning, which relies on accurate functional assessment. Recent studies have shown that functional connectivity (FC) of brain networks induced by upper extremity rehabilitation robotic training (UE-RAT) effectively reflects functional status, but its prognostic value for ADL remains unclear.

Objective
Utilize functional near-infrared spectroscopy (fNIRS) to measure FC during UE-RAT and develop machine learning models to evaluate the predictive value of task-FC for ADL.

Methods
This study recruited 86 patients with subacute stroke. Activation and FC features of key brain regions, such as the superior frontal cortex (SFC) and primary motor cortex (M1), were measured in the resting state and during UE-RAT using fNIRS. Concurrently, 38 clinical features were collected. With modified Barthel Index (mBI) ≥75 at discharge as the prediction target, machine learning algorithms such as artificial neural network (ANN) were used to construct resting-state fNIRS model, task-state fNIRS model, clinical model, and combined model, and analyze the importance of the predictor variables based on the Shapley additive interpretation (SHAP).

Results
The combined model constructed by combining clinical and task-state fNIRS features had the best predictive performance (AUC_mean: 0.955, 95% CI: 0.948–0.962). Higher connectivity between the ipsilateral premotor cortex (iPMC) and primary motor cortex (iM1) during the task state, along with higher mBI scores and lower mRS scores, predict significant improvement in functional independence for patients.

Conclusions
UE-RAT induced FC can be a valid biomarker for mBI prediction and can improve the accuracy of rehabilitation prediction.

Polyphenol consumption and neurodegeneration risk: A systematic meta-analysis of randomized controlled trials bridging nutrition and cognitive health

 Didn't your competent? doctor already create protocols for you on polyphenols? NO? So, totally fucking incompetent by not reading and implementing research? And the board of directors is no better? 

  • polyphenols (30 posts to Septenber 2012)
  • Polyphenol consumption and neurodegeneration risk: A systematic meta-analysis of randomized controlled trials bridging nutrition and cognitive health


    (Note: The full text of this document is currently only available in the PDF Version )

    Xiaomei Wang Jiao Yang Jiayuan Zhang Gaihong Yu Jian Zhu and Yingli Nie

    Received 26th November 2025 , Accepted 3rd January 2026

    First published on 6th January 2026

    Abstract

    Given the potential of polyphenols to mitigate neurodegenerative diseases (NDDs), this meta-analysis investigated whether clinical evidence supports the use of polyphenols for neuroprotection and as nutritional strategies in NDDs. We analyzed 14 polyphenol types across seven NDDs. From 15,073 records identified in Embase, Cochrane Library, PubMed, and Web of Science, 13 studies involving 849 participants were included. Prespecified outcomes comprised global cognition (Mini-Mental State Examination, MMSE), domain-specific cognition (Alzheimer’s Disease Cooperative Study–Cognitive Subscale, ADCS-Cog), activities of daily living (Alzheimer’s Disease Cooperative Study–Activities of Daily Living, ADCS-ADL), neuropsychiatric symptoms (Neuropsychiatric Inventory, NPI), and selected biomarkers (plasma amyloid-β40 and brain-derived neurotrophic factor, BDNF). Reporting followed PRISMA 2020 guidelines, methods conformed to the Cochrane Handbook, and certainty of evidence was assessed using GRADE. Overall, polyphenol supplementation was associated with improved global cognition (pooled MD in MMSE = 2.06; 95% CI 0.62–3.49). In subgroup analyses, flavonoids were associated with a modest but significant improvement in MMSE scores, whereas stilbenes produced a significant benefit in daily functioning (ADCS-ADL) without clear gains in MMSE or ADCS-Cog and no consistent effects on NPI. Anthocyanidins, phenolic acids, and lignans did not significantly affect cognitive outcomes (MMSE or ADCS-Cog), and polyphenol subclasses did not yield robust or consistent changes in NPI or biomarker endpoints (Aβ40 and BDNF). Specific polyphenol subclasses therefore appear to confer selective cognitive and functional benefits, with stilbenes primarily supporting functional outcomes and flavonoids potentially enhancing global cognition.

    AI-Stroke Accepted into Stanford StartX, Advances U.S. EMS Stroke Research with Leading Clinical and EMS Experts

    Are you that incompetent that you don't know of these fast diagnosis options?


    AI-Stroke Accepted into Stanford StartX, Advances U.S. EMS Stroke Research with Leading Clinical and EMS Experts

    Accepted into StartX Spring 2026, AI-Stroke advances U.S. EMS stroke research with new advisors, clinical studies, and NAEMSP engagement.

    Being selected by StartX is a key milestone as we prepare U.S. clinical studies and work closely with EMS partners to advance evidence-based stroke screening in real-world emergency settings.”

    — Simon Jiafeng Li

    PALO ALTO, CA, UNITED STATES, January 6, 2026 /EINPresswire.com/ — Palo Alto, California / Montpellier, France — January 6, 2026 — AI-Stroke, a healthcare AI company developing software to improve early stroke recognition in emergency settings, today announced its acceptance into StartX Spring 2026, Stanford University’s highly selective startup accelerator supporting clinically rigorous and venture-backed companies.

    Stroke remains one of the leading causes of death and long-term disability worldwide. Delayed or missed recognition in prehospital and early emergency settings contributes to avoidable neurological injury, higher post-acute care costs, and increased caregiver burden. AI-Stroke addresses this challenge by enabling faster, more accurate stroke screening(Faster than the above?) before CT imaging is available, using standard smartphones or tablets.

    StartX Acceptance Signals Execution Readiness

    AI-Stroke’s selection into StartX Spring 2026 places the company among a small cohort of startups supported by Stanford-affiliated clinicians, faculty, and experienced operators, with a strong focus on healthcare, life sciences, and responsible AI.

    As part of the program, Simon Jiafeng Li, Chief Business Officer and Co-Founder of AI-Stroke, will relocate to California for the duration of StartX to work closely with clinical, EMS, and academic partners.

    “Being physically present in California allows us to fully leverage the StartX ecosystem and ensure our upcoming U.S. clinical studies are executed smoothly and rigorously,” said Simon. “This is a critical phase for aligning technology, clinical evidence, and real-world EMS workflows.”

    Appointment of Leading EMS and Stroke Advisors

    To support U.S. EMS engagement and clinical execution, AI-Stroke has appointed Mic Gunderson and David Z. Rose, MD, as expert advisors.

    Mic Gunderson brings more than 50 years of experience across public, private, fire-based, and military EMS systems. He is currently the President of the Center for Systems Improvement and the EMS Quality Academy. He is also the Editor-In-Chief of the International Journal of Paramedicine.

    David Z. Rose, MD, is a vascular stroke neurologist and Professor at the University of South Florida Morsani College of Medicine, and serves as Co-Director of the Neuro-Cardiac Program and the 32-bed Neuro-ICU at Tampa General Hospital, a leading comprehensive stroke center. Triple-boarded in Internal Medicine, Neurology, and Stroke, Dr. Rose brings deep expertise in acute stroke care, neurocritical care, and hospital–EMS coordination.

    Engagement with Prehospital Stroke Leaders

    AI-Stroke recently presented its technology and clinical approach to members of the World Stroke Organization Taskforce for Prehospital Care (WSOTPC), including its Co-Chairs Dr. Renyu Liu (University of Pennsylvania) and Dr. Jing Zhao (Fudan University). AI-Stroke intends to align with established leaders in prehospital stroke care as it advances evidence generation and EMS-focused clinical research.

    Active Engagement with the U.S. EMS Community

    As part of its efforts to build U.S. EMS research collaborations, AI-Stroke will exhibit at the National Association of EMS Physicians (NAEMSP) 2026 Annual Meeting. Simon Jiafeng Li will represent the company at Booth 418, engaging with EMS medical directors, physicians, and system leaders interested in stroke research and prehospital innovation.

    Quantified Impact Designed for Emergency Care

    AI-Stroke’s software-as-a-medical-device uses computer vision and speech analysis to screen for strokes using basic medical data, short video recordings, and audio clips captured on standard smart devices. The assessment takes under two minutes to complete and will be fully compliant with existing CPSS/FAST protocols.

    In a study involving approximately 2,000 EMS professionals in France, AI-Stroke demonstrated around 15% higher sensitivity on key clinical signs of stroke. These findings are being used to inform prospective clinical studies and regulatory planning.

    Call for U.S. EMS Research Partnerships

    Over the next six months, AI-Stroke will focus on finalizing clinical study agreements with U.S. EMS partners and initiating studies to support FDA regulatory approval.

    EMS agencies, health systems, and academic partners interested in participating in clinical research, protocol development, or pilot studies are encouraged to engage in discussion, including at NAEMSP 2026.

    About AI-Stroke

    AI-Stroke is a Software as a Medical Device (SaMD) AI company focused on improving early stroke recognition and triage in emergency settings. Its software enables stroke screening using basic medical data, short video recordings, and audio clips captured on standard smartphones or tablets, delivering results in under two minutes. By supporting earlier, more accurate decision-making before imaging is available, AI-Stroke improves the sensitivity of stroke screening, enabling earlier intervention—a key factor in reducing long-term disability and optimizing stroke care cost management.

    Media Contact
    Simon Jiafeng Li
    Email: inquiries@ai-stroke.com
    Website: https://www.ai-stroke.com

    Simon Jiafeng Li
    AI-Stroke
    inquiries@ai-stroke.com
    Visit us on social media:
    LinkedIn
    Other

    Legal Disclaimer:

    EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
    for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
    article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

    Common dementia drug raises stroke risk – study

     There's a vicious circle here; stroke raises your risk of dementia substantially and taking this drug raise your stroke risk. Don't get caught in this infinite loop.

    With your risk of dementia post stroke your doctor and hospital (If competent) needs to have dementia prevention protocols on hand. 

    1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

    2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

    3. A 20% chance in this research.   July 2013.

    4. Dementia Risk Doubled in Patients Following Stroke September 2018  

    Do you prefer your doctor, hospital and board of director's incompetence NOT KNOWING? OR NOT DOING? Your choice; let them be incompetent or demand action!

    The latest here:

    Common dementia drug raises stroke risk – study

    Risperidone raises stroke risk in all patients, research finds, challenging the idea that any group can take the drug without added danger.

    The study of more than 165,000 people with dementia found risperidone increased stroke risk even in patients with no prior heart disease or stroke.

    Risperidone is a strong antipsychotic often prescribed for severe agitation in dementia, particularly in care homes when non-drug approaches have failed. Antipsychotics are medicines that can calm agitation and distress.

    The research, conducted by Brunel University London, challenges assumptions about who might safely use the drug and raises concerns about how risperidone is prescribed and monitored.

    Dr Byron Creese of Brunel University London said: “We knew risperidone causes stroke, but we didn’t know whether some groups of people might be more at risk than others.

    “We thought if we might identify characteristics that make people more at risk, doctors could avoid prescribing to patients with those characteristics.”

    Around half of people living with dementia experience agitation, which can cause intense distress for patients and carers.

    When non-drug treatments fail, risperidone is sometimes used as a last option. The findings underline the difficult choices faced by clinicians and families, who must balance potential benefits against elevated stroke risk.

    NHS guidelines limit risperidone use to six weeks for severe symptoms, but many patients take it longer, with monitoring standards varying across the country.

    There are no UK-licensed alternatives for risperidone in such cases, says Dr Creese, so risks should be clearly explained and carefully weighed.

    He said: “These findings give clearer information about who is most at risk, which helps everyone make more informed choices.

    “Every decision should be based on what is right for each person, through honest conversations between doctors, patients, and families.”

    The team analysed anonymised NHS records from 2004 to 2023, comparing patients prescribed risperidone with matched controls.

    In people with a history of stroke, the annual rate per 1,000 person-years was 22.2 on risperidone versus 17.7 without it. In those without prior stroke, rates were 2.9 versus 2.2.

    Risk was higher with short-term use of 12 weeks.

    Dr Creese said: “We hope that these data can be used in updated guidance that is more person-centred and based on particular patient characteristics.”

    Stem cell therapy for stroke shows how cells find their way in the brain

     Does this change existing understanding that stem cells were only good for generating exosomes and they were the beneficial parts to recovery?

    But why go thru all the trouble of stem cells if exosomes are the reason for the benefits? Which must be why no one seems to be monitoring stem cell survival.

    Application of stem cell-derived exosomes in ischemic diseases: opportunity and limitations

    Do you really think your incompetent? doctor and hospital can ensure human testing gets done?

    The latest here:

    Stem cell therapy for stroke shows how cells find their way in the brain

    Study shows neurons from grafted stem cells contain intrinsic codes for navigating and forming connections, may improve cell therapy for a brain short-circuited by stroke

    Peer-Reviewed Publication

    Sanford Burnham Prebys

    Grafted neurons illustration 

    image: 

    Illustration showing a transplanted nerve cell (gold) using its internal compass (code) to find its partner nerve cells in the brain and spinal cord (green).

    view more 

    Credit: Su-Chun Zhang, Sanford Burnham Prebys

    Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the cornea—can heal from minor scratches within a single day.

    The brain is not one of these fast-healing tissues or organs. Adult brain cells are stable and last for a lifetime barring trauma or disease, whereas some cells lining our guts last only five days and must be continually replaced.

    Scientists and physicians would like to use stem cell therapy to boost the brain’s ability to regenerate damage due to concussion or stroke. So far, these treatments have been stymied by changes in the brain due to injury, as well as difficulties with integrating regenerated cells into existing brain circuits to restore functions such as memory retention or motor skills.

    Scientists at Sanford Burnham Prebys Medical Discovery Institute and Duke-National University of Singapore (NUS) Medical School published findings January 8, 2026, in Cell Stem Cell from testing a therapy derived from human stem cells. When transplanted into mice, the cells matured, integrated into existing circuits and restored function. By tracing the cells and sequencing their gene expression patterns, the researchers also revealed how transplanted cells find where they need to go and form connections with the nervous system.

    The first challenge faced by hopeful regenerative medicine therapies for stroke and other forms of brain damage is the lack of a nurturing environment. Whereas the developing brain is a welcoming and instructive place for stem cells forming neurons and wiring the nervous system’s circuits, therapeutic cells arriving after a stroke find more hostility than hospitality.

    “In the adult brain after a stroke, you see the formation of a cyst, a cavity that is filled with all sorts of inflammatory molecules, so it is a bit like the therapeutic cells are swimming in a dangerous swamp full of threats,” said Su-Chun Zhang, MD, PhD, the Jeanne and Gary Herberger Leadership Chair in Neuroscience and the director of and professor in the Center for Neurologic Diseases at Sanford Burnham Prebys.

    “If that wasn’t enough, scar tissue surrounds the cavity to protect the brain from further damage, but it also forms a barrier against any potential regeneration.”

    Some cell therapy strategists try grafting new cells next to the damaged region of the brain where it is easier for the cells to survive and grow. The goal is to eventually reestablish circuits by bypassing the damaged region. Zhang feels that this trauma needs to be healed rather than side-stepped to reach the potential benefits of regenerative medicine.

    “Following a stroke, the damaged lesion is often very large and presents an immense challenge to efforts to functionally reconnect the brain to the brain stem and spinal cord.”

    Zhang and the research team sought to span this gap by developing a method to support the survival of therapeutic cells grafted directly into the harsh environment of the stroke cavity. Using a mixture of small molecule drugs and structural proteins, the scientists found that transplanted cells succeeded in surviving and growing to fill the damaged region.

    “Once transplanted cells can survive and become neurons, then we started asking whether those neurons can break through the scar tissue and grow functioning nerves by making new connections and reconstructing the disrupted circuits,” said Zhang.

    While the researchers had proven it was possible to transplant cells and grow new neurons, they knew it would be of little benefit if they didn’t form the correct kinds of connections. Were they rebuilding bridges that had been demolished, or creating new bridges to nowhere?

    “We found that different types of transplanted neurons found their own partners even in the complicated context of the mature brain environment,” said Zhang. “They still can find their targets in a very specific manner.”

    After conducting three-dimensional reconstruction of the transplanted neurons, the scientists observed that the patterns of long, spiny projections neurons use to form connections in the nervous system resembled the patterns seen in normal neurons populating the pathway between the cerebral cortex and spinal cord.

    Next, the scientists sought to better understand the navigational abilities of these regenerated neurons. They used a genetic barcode to label and trace the transplanted cells. This data was combined with the results of sequencing the transplanted cells’ gene expression profiles.

    “We revealed that each cell type has its own code and, once the cells become neurons, this code tells each cell to send its projections or axons to different parts of the brain and spinal cord,” said Zhang.

    “It’s the first time this striking phenomenon has been reported, and it is significant because it basically tells us that if we have the right types of transplanted cells, they already know where to go and what to do to repair what has been lost.”

    The scientists used machine learning to identify four subtypes of neurons that develop from transplanted therapeutic cells. Each subtype has a distinct expression of genes known to guide the growth of axons, which explains why most neurons of a particular subtype send axons to form circuits with the same brain region.

    The research team also validated how axonal projection patterns are affected by transcription factor proteins that modify gene expression. They tested stem cells modified without a transcription factor called Ctip2. These transplanted cells’ projection patterns varied significantly from those with the factor, with more axons seeking to form connections with the hippocampus and amygdala.

    “By learning more about these subtypes of transplanted neurons, we may be able to predict their projections and connectivity in order to select appropriate neuronal cell types for targeted circuit reconstruction in patients,” said Zhang.

    “It opens a promising future for cell therapy to help the millions of people that suffer from stroke and other devastating neurological conditions.”

     

    Zhifu Wang, PhD, a research fellow at Duke-National University of Singapore (NUS) Medical School, shares first authorship of the study with Danyi Zheng, PhD, a 2025 graduate of Duke-NUS Medical School.

    Additional authors include:

    • Phil Jun Kang, staff scientist at Sanford Burnham Prebys
    • Shu-Min Chou and Fei Ye from Duke-NUS Medical School

    The study was supported by the National Medical Research Council of Singapore and Duke-NUS Medical School.

    The study’s DOI is 10.1016/j.stem.2025.12.008.